Trial Profile
A phase I study of OX-382
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2018
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders; Pain
- Focus Adverse reactions
- 25 Jan 2018 According to an Orexo media release, trial results expected in Q2, 2018.
- 25 Jan 2018 Status changed from planning to recruiting, according to an Orexo media release.
- 19 Oct 2017 According to an Orexo media release, this trial is scheduled to start in the first quarter of 2018.